Earn CME/CE in your profession:

Continuing Education Activity

Proteinuria is a very common finding in outpatient as well as inpatient settings. Any such results warrant further investigation, especially in the setting of comorbidity. Given the rising trends of diabetes, proteinuria prevalence is on the rise. The primary etiology of proteinuria is the disturbance in the kidney filter. In addition to its association with early renal disease, it is also seen in benign conditions. Proteinuria has now also been used along with the estimated glomerular filtration rate (eGFR) in the classification of chronic kidney disease (CKD). Proteinuria can serve as an indicator of early renal disease. It marks an increased risk of renal damage secondary to hypertension and cardiovascular disease. The degree of proteinuria correlates with disease progression. This activity reviews the evaluation and management of proteinuria and explains the role of the interprofessional team in improving care for patients with this condition.


  • Identify the etiology of proteinuria.
  • Explain the evaluation of proteinuria.
  • List the management options available for proteinuria.
  • Summarize interprofessional team strategies for improving care coordination and communication in patients with proteinuria to ensure the best outcomes.


Proteinuria is a broad term used to describe protein in the urine. It is a general term for the presence of proteins, including albumin, globulin, Bence-Jones protein, and mucoprotein in the urine.[1] Almost half of the protein lost in normal urine is derived from the distal tubule, known as Tamm-Horsfall glycoprotein (THG).[2][3] Persistent proteinuria is a marker of kidney damage. It also helps with the diagnosis, prognosis, and therapy.[4][5]

The primary etiology of proteinuria is the disturbance in the kidney filter. In addition to its association with early renal disease, it is also seen in benign conditions.[6][7] Proteinuria has now also been used along with the estimated glomerular filtration rate (eGFR) in the classification of chronic kidney disease (CKD).[8] Proteinuria can serve as an indicator of early renal disease. It marks an increased risk of renal damage secondary to hypertension and cardiovascular disease.[9] The degree of proteinuria correlates with disease progression.[10]

According to the UK chronic kidney disease guidelines, proteinuria is defined as a urine protein creatinine ratio (UPCR) of more than 45 mg/mmol, but this does not warrant further evaluation in the absence of hematuria unless the UPCR is more than 100 mg/mmol.[3]

According to the NICE guidelines, proteinuria is defined as a UPCR of more than 50 mg/mmol or a urine albumin creatinine ratio (UACR) of more than 30 mg/mmol.[3][11]


Proteinuria can be classified as transient and persistent.

Transient Proteinuria

  • Urinary tract infection
  • Orthostatic proteinuria (occurs after the patient has been upright for a prolonged period, absent in early morning urine) - this is rare in patients more than 30 years of age[12]
  • Fever
  • Heavy exercise
  • Vaginal mucus
  • Pregnancy[9]

Persistent Proteinuria

  • Primary renal disease
    • Glomerular (such as glomerulonephritis)
    • Tubular[13]
  • Secondary renal disease
    • Diabetes mellitus
    • Connective tissue diseases 
    • Vasculitis
    • Amyloidosis
    • Myeloma[14]
    • Congestive cardiac failure
    • Hypertension[9]

Benign Causes of Proteinuria

  • Fever
  • Acute illness
  • Exercise/intense physical activity[15]
  • Orthostatic proteinuria[8]
  • Dehydration
  • Emotional stress
  • Hear injury
  • Inflammatory process[5]

The benign causes of proteinuria do not increase morbidity or mortality otherwise. These conditions are highly variable and usually reversible as the precipitating factor is addressed. Proteinuria is not a part of normal aging.[5]


The prevalence of proteinuria in the general population lies between 8% and 33%. The broad range is due to the variety of methods used to report proteinuria.[16][17][18] Due to its high prevalence, Japan has a screening program for proteinuria.[19][20] One of the major causes of renal disease and resultant proteinuria is the growing prevalence of type 2 diabetes mellitus. The prevalence of persistent proteinuria in affected individuals has been reported to be 15.3 per 1000 person-years. Less than 2% of patients with positive urine dipstick have a serious underlying etiology or urinary tract infection.[5] In the US, 3.3% of the adult population was observed to have persistent albuminuria with a normal eGFR.[21]


In a survey, it was found that the prevalence of microalbuminuria is greater in non-Hispanic Blacks and Mexican Americans compared with non-Hispanic Whites.[22]


Most primary and secondary renal diseases are more common in males than females. Persistent proteinuria is twice as common in males as in females.


Due to the increase in the incidence of hypertension and diabetes with age, persistent proteinuria and microalbuminuria also increase with age.


Proteinuria is a result of three different pathways, including:

  1. Glomerular dysfunction
  2. Tubulointerstitial disease
  3. Secretory proteinuria
  4. Overflow proteinuria

Glomerular Dysfunction

This is the most common cause of proteinuria. Glomerular dysfunction alters the permeability of the glomerular basement membrane leading to albuminuria and immunoglobinuria. Glomerular dysfunction causes urinary protein excretion of more than 2 g/24-hour.[5]

The glomerular filtration barrier is a three-layer membrane structure with the following layers (inner to outer):

  1. Fenestrated glomerular endothelium
  2. Glomerular basement membrane
  3. Podocyte[23]

The basement membrane of the glomerular capillary wall is responsible for restricting protein filtration owing to the presence of type 4 collagen. This filtration restriction is weight and size-based. As a result, larger and heavier proteins like albumin (molecular weight of 69000 D) are not seen in the urine under normal circumstances. In addition to the size and weight barrier, the negative charge on the glomerular capillary wall prevents the passage of negatively charged proteins like albumin.[1]

Glomerular proteinuria results from a damaged glomerular filtration barrier or increased hydrostatic pressure. Dysfunction of the charge barrier that consists of collagen and laminin leads to a loss of the negative charge, which manifests in the appearance of negatively charged proteins in the urine. In addition, mesangial cell growth in the glomerulus, extracellular matrix production, and infiltration with inflammatory cells can also lead to proteinuria. Podocytes are an essential barrier to proteinuria, and molecular dysfunction of nephrin and podocin at the level of podocytes can lead to the development of proteinuria. Transient receptor potential cation (TRPC) is a protein involved in calcium influx and has been shown to be associated with podocyte injury through an NFAT-mediated signaling pathway. The kidney also produces a membrane protein known as Klotho. In a recent study, klotho has been shown to suppress TRPC and hence may offer a therapeutic benefit for proteinuria in the future.[23]

Causes of glomerular dysfunction include:

  • Diabetic nephropathy (most common)
  • Drug-induced nephropathy (NSAIDs, lithium, heavy metals, heroin)[24]
  • Lymphoma[25]
  • Infections (HIV, hepatitis B, and C)
  • Primary glomerulonephropathies
  • Amyloidosis
  • Malignancies[5]
  • Dyslipidemia
  • Reactive oxygen species
  • Inflammatory cytokines
  • Activation of the renin-angiotensin system (RAS)[23]
  • Connective tissue diseases such as SLE

Chronic proteinuric glomerulopathy is defined as a sustained or permanent loss of protein filtration selectivity of the glomerulus.[23]

Tubulointerstitial Dysfunction

This is due to the dysfunction at the proximal tubule resulting in the impairment of the uptake of filtered proteins. Tubulointerstitial dysfunction usually leads to less severe proteinuria than glomerular dysfunction, with 24-hour urine protein levels of less than 2 grams.[5]

Smaller and positively charged proteins usually filtered through the glomerular capillary are absent in the urine owing to the nearly complete reabsorption by the tubular epithelial cells. Most of the protein reabsorption occurs in the proximal convoluted tubules. This reabsorption in the proximal convoluted tubules has a transport maximum which, when reached, can result in proteinuria.[1]

Causes of tubular dysfunction include:

  • Hypertensive nephrosclerosis
  • NSAIDs induced nephropathy[5]
  • Nephrotoxins
  • Chronic tubulointerstitial disease[1]

Secretory Proteinuria

Secretory proteinuria results from the oversecretion of specific proteins in the tubules, the most notable one being the Tamm-Horsfall proteins in interstitial nephritis.

Overflow Proteinuria

Increased production of proteins can saturate the reabsorptive channels in the proximal convoluted tubules leading to proteinuria. Overflow proteinuria occurs when the plasma concentration of low-molecular-weight proteins goes beyond the tubular capacity to reabsorb the filtered proteins.[26] Causes of overflow proteinuria include:

  • Multiple myeloma
  • Myoglobinuria
  • Amyloidosis[5]

History and Physical

Proteinuria may be asymptomatic, many patients do not report any symptoms, and proteinuria is detected on routine laboratory examination. A thorough history should be obtained from the patient, mainly asking about the symptoms of renal failure, including leg swelling and weight changes, as well as symptoms of connective tissue diseases, including arthralgias, skin rashes, and mouth ulcers.[27] Patients should be asked about loin pain, abdominal pain, shortness of breath, pleuritic chest pain, or rigors. A history of changes in the urine’s appearance (red/smoky, frothy) and its relation to an upper respiratory tract infection should also be obtained. In addition, a detailed history of comorbid conditions, including hypertension, diabetes mellitus, heart failure, etc., is required.

Thorough drug history is essential to rule out any nephrotoxic drug currently being used or used in the past as a possible cause of proteinuria. These include but are not limited to non-steroidal anti-inflammatory drugs (NSAIDs), antihypertensive drugs including angiotensin-converting enzyme (ACE) inhibitors, loop diuretics, and various antibiotics, especially penicillamine, aminoglycosides, and over-the-counter herbal medicines.[28] Detailed family history is essential to rule out familial renal and connective tissue diseases. The physical examination should focus on edema, muscle wasting, rashes, abdominal bruits, and splinter hemorrhages. On examination, there may be signs of systemic disease, e.g., retinopathy, joint swelling or deformity, stigmata of chronic liver disease, cardiac murmurs, organomegaly, and lymphadenopathy. Measurement of blood pressure can also help in making a diagnosis.[9]


Evaluation of a patient with proteinuria should begin with excluding urinary tract infection and the presence of diabetes mellitus. Urine dipsticks are the first screening tests for proteinuria that can be performed in an office. This is a semi-quantitative test in addition to being a qualitative test. The reading of proteinuria on a urine dipstick should be interpreted, considering the concentration of the urine reflected by the specific gravity. For instance, a urine dipstick value of 11 in a well-hydrated patient producing large quantities of dilute urine represents far more severe proteinuria than a dehydrated patient with similar values on a dipstick. The urine dipstick is semi-quantitative because although a reading of 11 on a dipstick shows proteinuria greater than 1 g/24 hour, it does not signify how much the value is greater than 1 g/24 hour.[8]

The urine dipstick diagnostic pad usually contains tetra bromophenol blue and citrate buffers. Several other dyes are also available that are more specific to albumin.[8][29][30] The pad detects the protein due to its electronegativity by changing color from yellow to blue. The mechanism used for protein detection by dipsticks should be considered because few proteins have a positive charge, like immunoglobulins. As a result, they are not detected on a urine dipstick. This problem can be solved using sulfosalicylic acid (SSA), which can detect immunoglobulins by flocculating. Similarly, alkaline urine will also change the color of the dipstick, giving a false positive.[30] Any positive results on dipstick and SSA should be further evaluated promptly.

Urine Dipstick Readings

False Positive

  • Dehydration
  • UTI
  • Hematuria
  • Alkaline urine pH of more than 8
  • Recent exercise

False Negative

  • Overhydration
  • Positively charged proteins (light chains)[8]

In order to quantify the degree of proteinuria, a 24-hour urine collection is entirely accurate but cumbersome to calculate the 24-hour urinary protein excretion in mg per 24 hours. Any value greater than 150 mg/24 hours is considered abnormal and should be further evaluated for underlying reasons.[9] The 24-hour urine collection is quite susceptible to overcollection or under-collection errors.[8]

An easier and reliable alternative is the spot urine protein to creatinine ratio (UPCR) from a single specimen, which should preferably be the early morning urine sample. [(mg/l protein)/(mmol/l creatinine)*10]. A UPCR value greater than 15 mg/mmol should raise suspicion and warrant further investigation.[9]

In addition to the protein levels, serum electrolytes, urea, and creatinine should be checked. For a nephrotic range of proteinuria with more than 3.5 g/24-hours or a UPCR of more than 350 mg/mmol, the serum albumin levels and cholesterol concentrations should be checked.[31] The value of proteinuria should be correlated with renal function tests. For example, a patient with UPCR values within normal limits with abnormal renal function tests, hematuria, and comorbidities should be evaluated.

Creatinine clearance is more helpful in evaluating renal function than creatinine levels. This can be calculated using some equations, such as the modification of diet in renal disease (MDRD), CKD-EPI equation, and the Cockcroft-Gault formula (as follows).

Creatinine clearance (ml/min) = [(140-age) X weight (kgs) X C] / serum creatinine (mol/l);

where C is 1.23 in males and 1.04 in females.

Normal creatinine clearance for a healthy young adult is more than 90 ml/min. It changes as the muscle mass changes in elderly patients and bodybuilders.[9] With aging, there is a decrease in creatinine clearance by 0.75 ml/min/year.[5][32] As a result, age and muscle mass should be considered with these values. For healthy adult males, the creatinine excretion ranges from 20 to 25 mg/kg/24 hours, whereas females excrete about 15- 20 mg/kg/24 hours. A healthy adult male of 70 kg will have 1400 to 1850 mg of creatinine excretion daily.[8]

Imaging (particularly renal ultrasonography), immunology screen (ANA, ANCA), and viral screen (hepatitis B and C ) are also helpful in diagnosing the underlying cause.[33]

Degrees of Proteinuria

  • Normal: Less than 150 mg/24 hour or 15 mg/mmol
  • Nephritic: 150-3000 mg/24 hour or 12-300 mg/mmol
  • Nephrotic: More than 3500 mg/24 hour or more than 350 mg/mmol

The type of protein constituting the proteinuria can be determined by immunoelectrophoresis.[34]

Albuminuria (mg/d)

    • Normal: Less than 30
    • Microalbuminuria: 30-300
    • Macroalbuminuria: More than 300[8]

Other Tests

  • Autoantibody determinations - including antistreptolysin O titers, antinuclear antibodies (ANAs), anti-DNA antibodies, complement levels (C3 and C4), anti-phospholipase A1 receptor autoantibody, and cryoglobulins
  • Hepatitis B and C and HIV serologies
  • Urine and plasma protein electrophoresis for light chains
  • Anti–glomerular basement membrane (anti-GBM) antibodies and antineutrophil cytoplasmic antibodies (ANCA)

Imaging Studies

  • Renal ultrasonography to review the size and echogenicity of the kidneys
  • Chest radiography or computed tomography may also be indicated

Renal Biopsy

Renal biopsy should be considered in patients with proteinuria above 1 g per day because it can guide the choice of a specific therapy.

Treatment / Management

The treatment of proteinuria is mainly focused on treating the specific underlying cause. In addition, most treatment modalities focus on reducing the degree of proteinuria, particularly albuminuria. These include drugs acting on the renin-angiotensin-aldosterone system. The 2013 Kidney Disease Improving Global Outcomes (KDIGO) guideline strongly recommends using ACE inhibitors or angiotensin receptor antagonists (ARB) in adults with more than 300 mg/24 hours of persistent proteinuria. The Chronic Kidney Disease Management publication by Kidney Health Australia in 2015 set the treatment target as a 50% reduction in albuminuria.[35]

Data obtained from multiple efficacy trials have shown the effectiveness of ACE inhibitors in reducing proteinuria in diabetic and nondiabetic patients. In addition to their effect on proteinuria, they have effectively reduced the risks of renal disease progression and hence, the requirement for renal replacement therapy.[36][37] As advised by Kidney Health Australia, the target of reducing proteinuria by 50% in the first six months to a year is associated with a similar decrease in the risk of renal disease progression.[35][38]

A study has shown that the efficacy of ACE inhibitors in halting the progression of proteinuria is more significant in patients with higher quantities of proteinuria than those with lower amounts of protein in the urine.[5][39] The initiation of therapy with ACE inhibitors requires a close check on creatinine and potassium levels. The current data does not show any significant difference between the efficacy and side effect profiles of both ACE inhibitors and ARBs. Hence the decision should be guided by the patient’s response and the provider’s experience.[35]

Combination therapies of ACE inhibitors with ARBs and direct renin inhibitors have been trialed in multiple studies showing an increased risk of adverse effects, including hyperkalemia, hypotension, renal impairment, and syncope.[40] Data is insufficient to recommend a combination of ACE and ARB to prevent any progression of renal disease. The Kidney Health Australia and the NICE guidelines in the UK do not recommend combination therapy for progression prevention in proteinuria.[35]


Patients with moderate to severe proteinuria have fluid overload and require diuretic therapy and dietary salt restriction. Aldosterone antagonists have also shown an advantage in their efficacy for proteinuria.[35] Combination therapy of ACE inhibitors with aldosterone antagonists is associated with an increased risk of hyperkalemia and gynecomastia. However, this combination has shown significant mortality benefits in patients with heart failure.[35][41]

Calcium Channel Blockers

Non-dihydropyridine calcium channel blockers (NDCCBs), diltiazem, and verapamil decrease proteinuria greater than dihydropyridine calcium channel blockers (DCCBs). The newer NDCCBs, such as efonidipine and benedipine, used in combination with ARBs, have reduced proteinuria.[42][43]

Differential Diagnosis

The presence of proteinuria in a patient requires a thorough evaluation and appropriate management to avoid developing complications.[1][5][8] The following differential diagnoses should be considered in a patient with proteinuria.[9][44][45]

  • Diabetic nephropathy
  • Orthostatic proteinuria
  • Nephrotoxins, drug-induced nephropathy (NSAIDs, lithium, heavy metals, heroin)
  • Infections (urinary tract infection, HIV, hepatitis B, and C)
  • Primary glomerulonephropathies, chronic tubulointerstitial disease
  • Amyloidosis
  • Post renal transplant
  • Preeclampsia
  • Malignancies (myeloma, lymphoma)
  • Dyslipidemia
  • Connective tissue diseases
  • Vasculitis
  • Congestive cardiac failure
  • Hypertension
  • Dehydration
  • Exercise/intense physical activity
  • Emotional stress


Studies have suggested that early recognition and management play a vital role in the prognosis of patients with proteinuria.[5] Proteinuria is used to assess the prognosis of many diseases. Proteinuria in IgA nephropathy is associated with a worse patient outcome.[46]

Similarly, higher proteinuria is correlated with a poor prognosis in patients with chronic kidney disease.[47] In idiopathic membranous nephropathy, the presence of proteinuria also reflects a poor prognosis.[48] Post-renal transplantation proteinuria is associated with higher mortality and reduced graft survival.[45] In a patient with preeclampsia, proteinuria reflects worse outcomes for both the mother and the fetus.[44]


Proteinuria is associated with significant complications, including increased risks of:

  • Coronary heart disease
  • Cerebrovascular disease[49][50]
  • Gastrointestinal hemorrhage[51]
  • Progression of kidney disease[52]
  • Hypercoagulability, Venous thromboembolism[53]
  • Pulmonary edema due to fluid overload
  • Bacterial infections
  • Renal replacement therapy, including dialysis and transplant
  • Death[5][35][54]

Studies have shown that microalbuminuria increases the risk of coronary artery disease by 50%, whereas the risk of cerebrovascular disease is increased by 70%. Macro-albuminuria is associated with doubling the risk for both.[35]


In addition to thorough evaluation and referral to a nephrologist, any patient with proteinuria should be assessed periodically, preferably every six months, while managing hypertension, diabetes, and other comorbidities.[9] A patient with proteinuria may require the following consultations during their diagnostic workup and management of the underlying factors and complications.

  • Nephrologist
  • Immunologist
  • Endocrinologist
  • Cardiologist
  • Neurologist
  • Gastroenterologist
  • Transplant team (transplant nephrologist, transplant surgeon, nurse, social worker, psychiatrist)

Deterrence and Patient Education

The urine collection over 24 hours requires that the urine collection process be educated to the patient clearly with clear written instructions.[8] The patient should be warned about the likely adverse effects of ACE inhibitors and angiotensin receptor blockers, including angioedema, dizziness, cough, syncope, hypotension, hyperkalemia, and a slightly increased risk of lung cancer.[35] Patients with moderate to severe proteinuria are in a fluid overload state, so salt restriction is also advised.

Enhancing Healthcare Team Outcomes

Proteinuria has no traditionally set cut-off values, varying from 150 to 300 mg/24 hours, depending upon the laboratory.[3] Any potential nephrotoxic drug should preferably be replaced if possible, or dosage adjustments should be made. In a patient with coexistent hypertension or heart failure, angiotensin-converting enzyme or angiotensin 2 receptor blockers should be the first line of management.[9]

An approach that is likely to benefit the patients is the gradual titration of ACE inhibitor or ARB dosages in increments, considering the patient’s individual response to drug tolerance and adverse effects.[35] Management of a patient with proteinuria requires an interprofessional team consisting of clinicians, nursing staff, nurses, pharmacists, and laboratory technicians. To accurately determine the underlying cause in these patients, open communication between all team members and specialties is crucial to getting the patient managed as expediently as possible. This also includes accurate record-keeping. This interprofessional approach utilizing open communication channels is necessary for optimal patient outcomes. [Level 5]


It is recommended to screen adults for one or more of the following risk factors:

  • Chronic kidney disease
  • Diabetes
  • Hypertension
  • Obesity
  • Current smoking
  • Cardiovascular disease
  • Family history of chronic kidney disease
  • Aboriginal or Torres Strait Islander people[35]

Screening is recommended because early recognition and management are associated with better outcomes regarding reduced morbidity and mortality.



Ahsan Aslam


9/4/2023 7:59:24 PM



Grauer GF. Proteinuria: measurement and interpretation. Topics in companion animal medicine. 2011 Aug:26(3):121-7. doi: 10.1053/j.tcam.2011.04.002. Epub     [PubMed PMID: 21782142]

Level 3 (low-level) evidence


Hoyer JR, Seiler MW. Pathophysiology of Tamm-Horsfall protein. Kidney international. 1979 Sep:16(3):279-89     [PubMed PMID: 393892]


Lamb EJ, MacKenzie F, Stevens PE. How should proteinuria be detected and measured? Annals of clinical biochemistry. 2009 May:46(Pt 3):205-17. doi: 10.1258/acb.2009.009007. Epub     [PubMed PMID: 19389884]


Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G, National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of internal medicine. 2003 Jul 15:139(2):137-47     [PubMed PMID: 12859163]

Level 1 (high-level) evidence


Verma V, Kant R, Sunnoqrot N, Gambert SR. Proteinuria in the elderly: evaluation and management. International urology and nephrology. 2012 Dec:44(6):1745-51. doi: 10.1007/s11255-012-0252-7. Epub 2012 Jul 25     [PubMed PMID: 22826147]


Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, Yusuf S, Mann JF, ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease). Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Annals of internal medicine. 2011 Mar 1:154(5):310-8. doi: 10.7326/0003-4819-154-5-201103010-00005. Epub     [PubMed PMID: 21357908]


Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, Jong PE, Coresh J, Chronic Kidney Disease Prognosis Consortium, Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, de Jong PE, Coresh J, El-Nahas M, Eckardt KU, Kasiske BL, Wright J, Appel L, Greene T, Levin A, Djurdjev O, Wheeler DC, Landray MJ, Townend JN, Emberson J, Clark LE, Macleod A, Marks A, Ali T, Fluck N, Prescott G, Smith DH, Weinstein JR, Johnson ES, Thorp ML, Wetzels JF, Blankestijn PJ, van Zuilen AD, Menon V, Sarnak M, Beck G, Kronenberg F, Kollerits B, Froissart M, Stengel B, Metzger M, Remuzzi G, Ruggenenti P, Perna A, Heerspink HJ, Brenner B, de Zeeuw D, Rossing P, Parving HH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney international. 2011 Jun:79(12):1331-40. doi: 10.1038/ki.2010.550. Epub 2011 Feb 2     [PubMed PMID: 21289598]

Level 1 (high-level) evidence


Snyder S, John JS. Workup for proteinuria. Primary care. 2014 Dec:41(4):719-35. doi: 10.1016/j.pop.2014.08.010. Epub 2014 Sep 27     [PubMed PMID: 25439530]


Haynes J, Haynes R. Proteinuria. BMJ (Clinical research ed.). 2006 Feb 4:332(7536):284     [PubMed PMID: 16455729]


Nielsen R, Christensen EI. Proteinuria and events beyond the slit. Pediatric nephrology (Berlin, Germany). 2010 May:25(5):813-22. doi: 10.1007/s00467-009-1381-9. Epub 2010 Jan 5     [PubMed PMID: 20049615]


National Collaborating Centre for Chronic Conditions (UK). Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. 2008 Sep:():     [PubMed PMID: 21413194]


Uehara K, Tominaga N, Shibagaki Y. Adult orthostatic proteinuria. Clinical kidney journal. 2014 Jun:7(3):327-8. doi: 10.1093/ckj/sfu040. Epub 2014 May 25     [PubMed PMID: 25852903]


Bökenkamp A. Proteinuria-take a closer look! Pediatric nephrology (Berlin, Germany). 2020 Apr:35(4):533-541. doi: 10.1007/s00467-019-04454-w. Epub 2020 Jan 10     [PubMed PMID: 31925536]


Gurung R, Li T. Renal Amyloidosis: Presentation, Diagnosis, and Management. The American journal of medicine. 2022 Apr:135 Suppl 1():S38-S43. doi: 10.1016/j.amjmed.2022.01.003. Epub 2022 Jan 24     [PubMed PMID: 35085515]


Kohler M, Schänzer W, Thevis M. Effects of exercise on the urinary proteome. Advances in experimental medicine and biology. 2015:845():121-31. doi: 10.1007/978-94-017-9523-4_12. Epub     [PubMed PMID: 25355575]

Level 3 (low-level) evidence


Lim D, Lee DY, Cho SH, Kim OZ, Cho SW, An SK, Kim HW, Moon KH, Lee MH, Kim B. Diagnostic accuracy of urine dipstick for proteinuria in older outpatients. Kidney research and clinical practice. 2014 Dec:33(4):199-203. doi: 10.1016/j.krcp.2014.10.003. Epub 2014 Nov 28     [PubMed PMID: 26885477]


Tomonaga Y, Risch L, Szucs TD, Ambühl PM. The prevalence of chronic kidney disease in a primary care setting: a Swiss cross-sectional study. PloS one. 2013:8(7):e67848. doi: 10.1371/journal.pone.0067848. Epub 2013 Jul 3     [PubMed PMID: 23844110]

Level 2 (mid-level) evidence


White SL, Yu R, Craig JC, Polkinghorne KR, Atkins RC, Chadban SJ. Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2011 Jul:58(1):19-28. doi: 10.1053/j.ajkd.2010.12.026. Epub 2011 Mar 15     [PubMed PMID: 21411199]


Bezinque A, Noyes SL, Kirmiz S, Parker J, Dey S, Kahnoski RJ, Lane BR. Prevalence of Proteinuria and Other Abnormalities in Urinalysis Performed in the Urology Clinic. Urology. 2017 May:103():34-38. doi: 10.1016/j.urology.2017.02.011. Epub 2017 Feb 14     [PubMed PMID: 28212852]


Yamagata K, Iseki K, Nitta K, Imai H, Iino Y, Matsuo S, Makino H, Hishida A. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clinical and experimental nephrology. 2008 Feb:12(1):1-8. doi: 10.1007/s10157-007-0010-9. Epub 2008 Jan 5     [PubMed PMID: 18175065]

Level 3 (low-level) evidence


Jones CA, Francis ME, Eberhardt MS, Chavers B, Coresh J, Engelgau M, Kusek JW, Byrd-Holt D, Narayan KM, Herman WH, Jones CP, Salive M, Agodoa LY. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2002 Mar:39(3):445-59     [PubMed PMID: 11877563]

Level 3 (low-level) evidence


Bryson CL, Ross HJ, Boyko EJ, Young BA. Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes and level of CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2006 Nov:48(5):720-6     [PubMed PMID: 17059991]

Level 3 (low-level) evidence


Liu D, Lv LL. New Understanding on the Role of Proteinuria in Progression of Chronic Kidney Disease. Advances in experimental medicine and biology. 2019:1165():487-500. doi: 10.1007/978-981-13-8871-2_24. Epub     [PubMed PMID: 31399981]

Level 3 (low-level) evidence


Gong R, Wang P, Dworkin L. What we need to know about the effect of lithium on the kidney. American journal of physiology. Renal physiology. 2016 Dec 1:311(6):F1168-F1171. doi: 10.1152/ajprenal.00145.2016. Epub 2016 Apr 27     [PubMed PMID: 27122541]


Sfrijan D, Tieranu I, Necula I, Popa L, Balgradean M. Nephrotic Syndrome, Paraneoplastic Syndrome Associated to Hodgkin Lymphoma. Maedica. 2016 Mar:11(1):64-67     [PubMed PMID: 28465754]


Leung AK, Wong AH, Barg SS. Proteinuria in Children: Evaluation and Differential Diagnosis. American family physician. 2017 Feb 15:95(4):248-254     [PubMed PMID: 28290633]


Uva L, Miguel D, Pinheiro C, Freitas JP, Marques Gomes M, Filipe P. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune diseases. 2012:2012():834291. doi: 10.1155/2012/834291. Epub 2012 Jul 25     [PubMed PMID: 22888407]


Ağbaş A, Bay ED, Başaran MK, İkizceli T, Kayhan GK, Özlük Y. Nephrotic range proteinuria in an adolescent with a diagnosis of Wilson's disease: Answers. Pediatric nephrology (Berlin, Germany). 2021 Jul:36(7):2103-2106. doi: 10.1007/s00467-021-04961-9. Epub 2021 Feb 2     [PubMed PMID: 33528637]


WILLS MR, MCGOWAN GK. THE RELIABILITY OF THE ALBUSTIX TEST FOR PROTEINURIA. Journal of clinical pathology. 1963 Sep:16(5):487     [PubMed PMID: 14063342]


Pugia MJ, Lott JA, Profitt JA, Cast TK. High-sensitivity dye binding assay for albumin in urine. Journal of clinical laboratory analysis. 1999:13(4):180-7     [PubMed PMID: 10414598]


Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney international. 2016 Jul:90(1):41-52. doi: 10.1016/j.kint.2016.02.026. Epub 2016 Apr 26     [PubMed PMID: 27165836]


Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. Journal of the American Geriatrics Society. 1985 Apr:33(4):278-85     [PubMed PMID: 3989190]


Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World journal of gastroenterology. 2014 Jun 28:20(24):7544-54. doi: 10.3748/wjg.v20.i24.7544. Epub     [PubMed PMID: 24976695]


Lyubimova NV, Timofeev YS, Abaev VM, Votyakova OM, Kushlinskii NE. Immunochemical Diagnosis of Multiple Myeloma. Bulletin of experimental biology and medicine. 2018 May:165(1):84-87. doi: 10.1007/s10517-018-4105-y. Epub 2018 May 24     [PubMed PMID: 29797132]


Athavale A, Roberts DM. Management of proteinuria: blockade of the renin-angiotensin-aldosterone system. Australian prescriber. 2020 Aug:43(4):121-125. doi: 10.18773/austprescr.2020.021. Epub 2020 Aug 3     [PubMed PMID: 32921887]


Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. The New England journal of medicine. 1993 Nov 11:329(20):1456-62     [PubMed PMID: 8413456]


. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet (London, England). 1997 Jun 28:349(9069):1857-63     [PubMed PMID: 9217756]

Level 1 (high-level) evidence


Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clinical journal of the American Society of Nephrology : CJASN. 2008 Jan:3 Suppl 1(Suppl 1):S3-10. doi: 10.2215/CJN.03250807. Epub     [PubMed PMID: 18178794]


National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2002 Feb:39(2 Suppl 1):S1-266     [PubMed PMID: 11904577]

Level 2 (mid-level) evidence


ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England journal of medicine. 2008 Apr 10:358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31     [PubMed PMID: 18378520]


Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England journal of medicine. 1999 Sep 2:341(10):709-17     [PubMed PMID: 10471456]

Level 1 (high-level) evidence


Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. The American journal of physiology. 1989 Jun:256(6 Pt 2):F1015-20     [PubMed PMID: 2544103]


Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney international. 1998 Sep:54(3):889-96     [PubMed PMID: 9734613]


Tanacan A, Fadiloglu E, Beksac MS. The importance of proteinuria in preeclampsia and its predictive role in maternal and neonatal outcomes. Hypertension in pregnancy. 2019 May:38(2):111-118. doi: 10.1080/10641955.2019.1590718. Epub 2019 Apr 2     [PubMed PMID: 30939965]


Tsampalieros A, Knoll GA. Evaluation and Management of Proteinuria After Kidney Transplantation. Transplantation. 2015 Oct:99(10):2049-60. doi: 10.1097/TP.0000000000000894. Epub     [PubMed PMID: 26335919]


Reich HN, Troyanov S, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry. Remission of proteinuria improves prognosis in IgA nephropathy. Journal of the American Society of Nephrology : JASN. 2007 Dec:18(12):3177-83     [PubMed PMID: 17978307]


Iimori S, Naito S, Noda Y, Sato H, Nomura N, Sohara E, Okado T, Sasaki S, Uchida S, Rai T. Prognosis of chronic kidney disease with normal-range proteinuria: The CKD-ROUTE study. PloS one. 2018:13(1):e0190493. doi: 10.1371/journal.pone.0190493. Epub 2018 Jan 17     [PubMed PMID: 29342207]


Chen X, Chen Y, Ding X, Zhou Y, Lv Y, Li D, Chen B, Chen T, Chen C. Baseline proteinuria level is associated with prognosis in idiopathic membranous nephropathy. Renal failure. 2019 Nov:41(1):363-369. doi: 10.1080/0886022X.2019.1605294. Epub     [PubMed PMID: 31057017]


Naderi AS, Reilly RF. Primary care approach to proteinuria. Journal of the American Board of Family Medicine : JABFM. 2008 Nov-Dec:21(6):569-74. doi: 10.3122/jabfm.2008.06.070080. Epub     [PubMed PMID: 18988725]


Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, Jardine M, Gallagher M, Turnbull F, Chalmers J, Craig J, Huxley R. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS medicine. 2008 Oct 21:5(10):e207. doi: 10.1371/journal.pmed.0050207. Epub     [PubMed PMID: 18942886]

Level 1 (high-level) evidence


Ishigami J, Grams ME, Naik RP, Coresh J, Matsushita K. Chronic Kidney Disease and Risk for Gastrointestinal Bleeding in the Community: The Atherosclerosis Risk in Communities (ARIC) Study. Clinical journal of the American Society of Nephrology : CJASN. 2016 Oct 7:11(10):1735-1743. doi: 10.2215/CJN.02170216. Epub 2016 Aug 11     [PubMed PMID: 27515592]


Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? Journal of the American Society of Nephrology : JASN. 2006 Nov:17(11):2974-84     [PubMed PMID: 17035611]


Gigante A, Barbano B, Sardo L, Martina P, Gasperini ML, Labbadia R, Liberatori M, Amoroso A, Cianci R. Hypercoagulability and nephrotic syndrome. Current vascular pharmacology. 2014 May:12(3):512-7     [PubMed PMID: 22724465]


Jun M, Ohkuma T, Zoungas S, Colagiuri S, Mancia G, Marre M, Matthews D, Poulter N, Williams B, Rodgers A, Perkovic V, Chalmers J, Woodward M, ADVANCE Collaborative Group. Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON. Diabetes care. 2018 Jan:41(1):163-170. doi: 10.2337/dc17-1467. Epub 2017 Oct 27     [PubMed PMID: 29079715]

Level 2 (mid-level) evidence